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Background: Zolpidem, a short-acting non-benzodiazepine GABA agonist hypnotic, has
been shown to induce paradoxical responses in some patients with disorders of
consciousness (DOC), leading to recovery of arousal and cognitive abilities. We here
assessed zolpidem-induced changes in regional brain metabolism in three patients with
known zolpidem response in chronic post-anoxic minimally conscious state (MCS).
Methods: [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) and
standardized clinical assessments using the Coma Recovery Scale-Revised were
performed after administration of 10mg zolpidem or placebo in a randomized double
blind 2-day protocol. PET data preprocessing and comparison with a healthy age-matched
control group were performed using statistical parametric mapping (SPM8).
Results: Behaviorally, all patients recovered functional communication after administration
of zolpidem (i.e., emergence from the MCS). FDG-PET showed increased metabolism
in dorsolateral prefrontal and mesiofrontal cortices after zolpidem but not after placebo
administration.
Conclusion: Our data show a metabolic activation of prefrontal areas, corroborating the
proposed mesocircuit hypothesis to explain the paradoxical effect of zolpidem observed
in some patients with DOC. It also suggests the key role of the prefrontal cortices in
the recovery of functional communication and object use in hypoxic patients with chronic
MCS.
Keywords: minimally conscious state, zolpidem, brain metabolism, positron emission tomography, prefrontal
cortex, mesocircuit hypothesis
INTRODUCTION
Following a severe brain injury, patients can stay in a prolonged
period of unconsciousness. They can be in a coma for few days
or weeks, before evolving into a vegetative/unresponsive wakeful-
ness syndrome (i.e., eyes open but only showing reflex behaviors
Laureys et al., 2010) or into a minimally conscious state (MCS,
Giacino et al., 2002). MCS is characterized by inconsistent but
reproducible evidence of awareness (e.g., signs of conscious-
ness without command following- MCS minus; with command
following- MCS plus, Bruno et al., 2011). Emergence from MCS
(EMCS) is characterized by the recovery of functional commu-
nication and/or functional object use. According to the Coma
Recovery Scale-Revised assessment (CRS-R, Giacino et al., 2004),
functional communication is reached when a patient is able to
answer 6 out of 6 “yes–no” questions accurately. Communication
is intentional if (s)he is able to answer at least 2 out of 6 questions
independently of accuracy. Functional object use encompasses
the ability to accurately use two different objects two times.
Research on efficient treatments improving cognitive abilities in
this population of patients with MCS has shown that deep brain
stimulation (Schiff et al., 2007) and some pharmacological agents
such as amantadine (Schnakers et al., 2008a; Giacino et al., 2012),
apomorphine (Fridman et al., 2009) intrathecal baclofen (Sara
et al., 2007) and zolpidem (Whyte and Myers, 2009; Thonnard
et al., 2013) can improve recovery in some cases (for a recent
review, see Gosseries et al., 2013). However, the mechanisms
underlying these recoveries remain poorly understood.
Zolpidem is a short-acting non-benzodiazepine agent from
the imidazopyridine class usually used against insomnia (Langtry
and Benfield, 1990; Sanger, 2004). It has been shown to induce
paradoxical responses in some patients with disorders of con-
sciousness (DOC), leading to an improvement of arousal and
cognitive abilities. Several case-studies showed that it can induce
very impressive recoveries in severely brain-damaged patients
with DOC of various etiologies (Clauss et al., 2000; Cohen
et al., 2004; Clauss and Nel, 2006; Brefel-Courbon et al., 2007;
Shames and Ring, 2008; Williams et al., 2013). However, this
effect remains rare (i.e., around 5–7% of responders; Whyte and
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Myers, 2009; Thonnard et al., 2013; Whyte et al., 2014) and it
is not always significant in terms of functional recovery (in the
7% of the patients showing improvement, no diagnosis changes
was observed in Thonnard et al., 2013). A change in brain activ-
ity (e.g., prefrontal cortices, thalami and striatum) after zolpidem
intake has been reported in single subject studies using single-
photon emission computed tomography (measuring blood flow)
(Clauss et al., 2000), positron emission tomography (PET, Brefel-
Courbon et al., 2007; Williams et al., 2013; measuring blood flow
and metabolism), and electroencephalography (EEG; measuring
electrical activity Williams et al., 2013).
We here assessed zolpidem-induced changes in regional brain
metabolism in a case-series of three patients with known zolpi-
dem response after chronic post-anoxic MCS. According to the
mesocircuit model for the recovery of consciousness (Schiff,
2010), zolpidem is suggested to disinhibit the globus pallidus
interna (GPi) and by that way increase the thalamic excitatory
role on prefrontal cortices (see Figure 1). Based on this model, we
hypothesized that an impaired brain metabolism in the thalamus,
striatum and prefrontal areas would be observed at the group level
during placebo, which would recover following zolpidem intake.
MATERIALS AND METHODS
Three patients with chronic post-anoxic MCS with known clini-
cal improvement to zolpidem administration (i.e., EMCS) were
included in the study. All patients took zolpidem on a regu-
lar basis for at least 6 months. For the present study, zolpidem
intake was stopped at least 12 h prior to the research protocol.
10mg of zolpidem or placebo (water) were administered at 12
a.m. via gastrostomy in a randomized order, in a double blind
2-day design. All other treatments remained unchanged through-
out the study. Standardized clinical assessment using the CRS-R
(Giacino et al., 2004; Schnakers et al., 2008b) was performed
30min after administration of zolpidem or placebo. The CRS-R
is a validated and sensitive behavioral assessment scale to deter-
mine patients’ level of consciousness (Seel et al., 2010). It assesses
auditory, visual, verbal, and motor functions as well as communi-
cation and arousal level. The total score ranges between 0 (coma)
and 23 (EMCS).
FDG-PET cerebral metabolism data were acquired 90min
after zolpidem or placebo intake, at the University Hospital of
Liège using a Gemini TF Big Bore (Philips Medical System)
and according to a standard clinical protocol. An intra-
venous injection of 300MBq fluorodeoxyglucose was admin-
istered 30min before the FDG-PET. Patients were monitored
by an anesthesiologist throughout the procedure. The study
was approved by the Ethics Committee of the Faculty of
Medicine of the University of Liège and written informed con-
sent was obtained from the patients’ legal representatives and all
volunteers.
FIGURE 1 | The mesocircuit model underlying forebrain dysfunction and
interventions in severe brain injuries (From Giacino et al., 2014, with
permission). Reduction of thalamocortical and thalamostriatal outflow
following deafferentation and neuronal loss from the central thalamus
withdraws the afferent drive to the striatum, which may then fail to reach firing
threshold because of their requirement for high levels of synaptic background
activity. Loss of active inhibition from the striatum allows neurons of the
globus pallidus interna to tonically fire and provide active inhibition to their
synaptic targets, including relay neurons of the already disfacilitated central
thalamus, and possibly also the projection neurons of the pedunculopontine
nucleus. Since the GABAA a-1 subunit is normally expressed in large
quantities in the globus pallidus interna, zolpidem could inhibit the latter,
substituting its normal inhibition from the striatum, and hence induce an
increase of the thalamic excitatory influence on prefrontal cortices.
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PET data of patients were compared to an age-matched group
of 39 healthy participants (mean age 45 ± 16 years; 18 men).
Preprocessing of the PET data was identical as previously pub-
lished (Phillips et al., 2011; Bruno et al., 2012; Thibaut et al., 2012)
including spatial normalization and smoothing (using a 14mm
full width at a half maximum Gaussian kernel), implemented in
Statistical Parametric Mapping toolbox (SPM8; www.fil.ion.ucl.
ac.uk/spm).
The statistical analyses were also performed using SPM8 tool-
box. A full-factorial design with three design matrices modeled
the subject-effect (MCS patient 1, 2, 3), drug-effect (placebo
vs. zolpidem) and group effect (patients vs. controls) was per-
formed. After proportional scaling, we identified brain regions
that showed a relative increase in metabolism after zolpidem
intake as compared to placebo. Areas showing an impaired
metabolism after placebo and after zolpidem intake as compared
to healthy controls were also investigated. Results were consid-
ered significant at false discovery rate cluster level p < 0.001 after
a Bonferroni correction for multiple comparisons.
CASE REPORTS
Table 1 shows the CRS-R subscores after placebo and zolpidem
intake.
MCS 1
A 37-year-old female was assessed 18months post anoxia (cardio-
respiratory arrest after hanging). Within the month post-insult,
she emerged from the vegetative state/unresponsive wakefulness
Table 1 | Behavioral assessments after placebo and zolpidem intake (based on the Coma Recovery Scale-Revised).
MCS 1 MCS 2 MCS 3
P Z P Z P Z
AUDITORY FUNCTION
4—Consistent Movement to Command*
3—Reproducible Movement to Command*
2—Localization to Sound
1—Auditory Startle
0—None
VISUAL FUNCTION SCALE
5—Object Recognition*
4—Object Localization: Reaching*
3—Pursuit Eye Movements*
2—Fixation*
1—Visual Startle
0—None
MOTOR FUNCTION SCALE
6—Functional Object Use†
5—Automatic Motor Response*
4—Object Manipulation*
3—Localization to Noxious Stimulation*
2—Flexion Withdrawal
1—Abnormal Posturing
0—None/Flaccid
OROMOTOR/VERBAL FUNCTION SCALE
3—Intelligible Verbalization*
2—Vocalization/Oral Movement
1—Oral Reflexive Movement
0—None
COMMUNICATION SCALE
2—Functional: Accurate†
1—Non-Functional: intentional*
0—None
AROUSAL SCALE
3—Attention
2—Eye Opening w/o Stimulation
1—Eye Opening with Stimulation
0—Unarousable
DIAGNOSIS MCS+ EMCS MCS− EMCS MCS+ EMCS
MCS−, minimally conscious state minus (i.e., non reflex movements without response to command); MCS+, minimally conscious state plus (i.e., presence of
response to command); EMCS, emergence from the minimally conscious state (i.e., functional communication or object use).
*Indicates clinical signs compatible with MCS. †Indicates emergence from minimally conscious state. P, placebo; Z, zolpidem. Highest score achieved for each
subscale is represented by the black boxes.
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syndrome and evolved into a MCS plus. CRS-R assessment
showed reproducible but not consistent command following,
visual pursuit, and intentional communication. MRI showed
ischemic brain lesions in the basal ganglia, in the left occipi-
tal and bilateral posterior parietal cortices. Resting EEG showed
a reactive background rhythm of alpha/theta activity (7–8Hz)
without any epileptic activity. After zolpidem administration, she
could systematically follow simple commands, recognize different
objects and use them adequately, and communicate function-
ally (i.e., EMCS). Concurrent treatment consisted of amantadine,
fluoxetine, trihexyphenidyl, tramadol, and esomeprazole.
MCS 2
A 38-year-old male was assessed 12 years and 7 months post-
anoxia (cardio-respiratory arrest after hanging). The patient
showed visual pursuit and automatic motor reactions (i.e., mouth
opening when a spoon was brought to his mouth), and was
diagnosed as MCS minus. The MRI showed lesions in the brain-
stem and in the thalami with diffuse periventricular white matter
damage, more pronounced in posterior regions and in the left
hemisphere. Resting EEG showed a background rhythm of 7Hz
theta activity without epileptic activity. After zolpidem adminis-
tration, he was able to systematically follow simple commands,
recognize objects and use them consistently, and communicate
functionally (i.e., EMCS). Concurrent treatment consisted of
levetiracetam.
MCS 3
A 50-year-old female was assessed 7 years post anoxia (cardio-
respiratory arrest after hanging). Structural MRI did not show
focal abnormalities (PET glucose and activation blood-flow
data have been reported elsewhere, Brefel-Courbon et al.,
2007). She remained 3 weeks in a coma before recovering
signs of consciousness. CRS-R assessment showed automatic
motor reactions (i.e., pulling on her shirt), reproducible but
not consistent command following, localization of objects,
and intentional communication (i.e., MCS plus). Resting
EEG recordings did not demonstrate any epileptic discharges
with a background rhythm of 6Hz theta activity. Following
zolpidem intake, she showed consistent command following,
functional use of objects, and functional communication (i.e.,
EMCS). Concurrent treatment consisted of modafinil, fluoxe-
tine, piribedil, dihydroergocristine, domperidone, vinburnine,
heptaminol, and omeprazole.
RESULTS
Group level analysis showed a relative increase in the bilateral
superior frontal gyri and the right medial frontal cortex fol-
lowing zolpidem intake as compared to placebo (Table 2 and
Figures 2, 3). At a less conservative statistical threshold uncor-
rected for multiple comparisons, the left insula, the middle
frontal gyri and the left inferior frontal and parietal areas also
showed a relative increase following zolpidem intake as com-
pared with placebo. During placebo, the thalami and the left
precuneus/posterior cingulate areas showed an impaired brain
metabolism as compared with healthy controls. At a less conser-
vative statistical threshold, bilateral superior and middle frontal
gyri, the left precuneus/posterior cingulate, bilateral precen-
tral gyri, left insula and right inferior parietal areas showed
an impaired brain metabolism. After zolpidem intake, the tha-
lami and the left precuneus/posterior cingulate areas showed an
impaired brain metabolism as compared with healthy controls.
At a less conservative threshold, the precentral gyri, left superior
frontal and temporal gyri, the left middle frontal gyrus and pre-
cuneus and the right inferior parietal lobe showed an impaired
brain metabolism.
DISCUSSION
Using a double-blind placebo-controlled design, we here report
FDG-PET changes after the administration of zolpidem in three
chronic post-anoxic patients in MCS who show clinically sig-
nificant paradoxical behavioral improvements (i.e., EMCS). We
observed that zolpidem-related recovery of cognitive abilities was
paralleled by an increase in glucose metabolism in bilateral dorso-
lateral prefrontal and mesiofrontal cortices. Our findings support
previous case-studies reporting a change in prefrontal cortex
activity after zolpidem intake using single-photon emission com-
puted tomography (Clauss et al., 2000), PET (Brefel-Courbon
et al., 2007; Williams et al., 2013) and EEG (Williams et al.,
2013). Prefrontal areas are known to be involved in the “lim-
bic loop” regulation of motivation and are a key center of the
mesocircuit model for consciousness (Schiff, 2010; Laureys and
Schiff, 2012). The mesocircuit hypothesis for the effect of zolpi-
dem (Schiff, 2010) supports the idea that, in normal cognitive
processing, the striatum disinhibits the central thalamus via the
internal globus pallidus (GPi) while the central thalamus pro-
motes activity of prefrontal cortices. Therefore, if the activity in
the striatum is reduced (e.g., following a severe brain injury),
central thalamic and prefrontal activities are also reduced, pos-
sibly explaining the observed hypometabolism of the latter in
the here reported patients in the baseline condition (i.e., after
placebo administration). Since the GABAA a-1 subunit is nor-
mally expressed in large quantities in the GPi, zolpidem could
inhibit the GPi, substituting the normal inhibition of the GPi
from the striatum. The mesocircuit model assumes that zolpidem
directly inhibits the GPi, substituting the normal inhibition of the
GPi from the striatum (one of the most sensitive areas to cerebral
hypoxia Calabresi et al., 2000) and would hence increase the tha-
lamic excitatory influence on prefrontal cortices. Interestingly, in
all studies with zolpidem responders (Clauss et al., 2000; Brefel-
Courbon et al., 2007), including ours, the brain areas showing
increased metabolism after zolpidem did not show significant
structural lesions. This could support the idea that patients who
respond to zolpidem have neurologic deficits mainly caused by
inhibitory functional effects rather than by severely structurally
damaged or dead brain tissue (Shames and Ring, 2008). This
effect is defined as cerebral diashisis, i.e., the loss of function
in a portion of the brain (here, the prefrontal cortices) as a
result of its connection to another injured area (here, striatum
and/or thalami) (Glassman, 1971; Feeney and Baron, 1986; Tecco
et al., 1998; Witte et al., 2000). It has been proposed that zolpi-
dem may be effective to restore brain function in patients whose
brain injuries are mainly located outside of brainstem struc-
tures (Du et al., 2014). However, in our three responders one
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Table 2 | Regions showing significant impaired metabolism following placebo and zolpidem and relative increase following zolpidem intake.
Region (Brodmann area) X (mm) Y (mm) Z (mm) Z -value P-value
IMPAIRED AFTER PLACEBO
Right thalamus 12 −16 10 6.15 ≤0.0001**
Left thalamus −12 −16 12 6.11 ≤0.0001**
Left posterior cingulate cortex (B31) −2 −28 34 5.98 ≤0.0001**
Left middle frontal gyrus (B6) −34 18 60 4.00 ≤0.0001*
Left superior frontal gyrus (B6/10) −20 14 70 3.64 ≤0.0001*
Left precuneus (B19) −44 −70 42 3.93 ≤0.0001*
Right precentral gyrus (B6) 36 −12 70 3.86 ≤0.0001*
Right middle frontal gyrus (B6) 48 12 56 3.63 ≤0.0001*
Right superior frontal gyrus (B8) 32 30 56 3.50 ≤0.0001*
Left insula (B13) −46 6 −2 3.51 ≤0.0001*
Right inferior parietal lobe (B40) 64 −32 48 3.25 ≤0.001*
Left precentral gyrus (B6) −38 −16 68 3.19 ≤0.001*
IMPAIRED AFTER ZOLPIDEM
Right thalamus 12 −16 10 6.34 ≤0.0001**
Left thalamus −10 −16 10 6.24 ≤0.0001**
Left posterior cingulate cortex (B31) −2 −28 34 5.95 ≤0.0001**
Right precentral gyrus (B6/4) 36 −12 70 4.02 ≤0.0001*
Left superior frontal gyrus (B6/8) −14 16 70 9.77 ≤0.0001*
Left middle frontal gyrus (B6) −32 20 60 3.63 ≤0.0001*
Left precuneus (B19) −42 −70 44 3.57 ≤0.0001*
Left precentral gyrus (B6) −38 −16 68 3.51 ≤0.0001*
Right inferior parietal lobe (B40) 64 −30 48 3.37 ≤0.0001*
Left superior temporal gyrus (B22) −46 4 −4 3.29 ≤0.0001*
RELATIVE INCREASE AFTER ZOLPIDEM AS COMPARED TO PLACEBO
Left superior frontal gyrus (B10) −22 56 24 4.35 ≤0.0001**
Right superior frontal gyrus (B10) 12 60 20 4.35 ≤0.0001**
Right medial frontal gyrus (B9) 8 42 32 4.05 ≤0.0001**
Left insula (B13) −44 14 2 3.37 ≤0.0001*
Left inferior frontal gyrus (B47) −34 20 −8 3.32 ≤0.0001*
Left middle frontal gyrus (B8) −54 14 42 3.34 ≤0.0001*
Left angular gyrus (B39) −46 −62 34 3.22 ≤0.001*
Right middle frontal gyrus (B9) 44 18 28 3.24 ≤0.001*
Left inferior parietal lobe (B40) −44 −54 42 3.22 ≤0.001*
coordinates of peak voxels in standardized stereotaxic MNI space.
**Corrected p-value for multiple comparisons.
*Uncorrected p-value.
did show structural brainstem lesions (Du et al., 2013). In con-
trast to two previous case-studies (Brefel-Courbon et al., 2007;
Williams et al., 2013), we did not observe a zolpidem-related
increase in metabolism in thalamic and striatal regions. This
could be explained either by the fact that the technique used is not
sensitive enough to highlight small functional activity changes in
these areas, or because zolpidem induced changes might modify
effective connectivity between areas which cannot be investigated
using FDG-PET. Future neuroimaging studies looking at effec-
tive connectivity in DOC zolpidem-responders would allow to
better document the role of thalamo-cortico excitatory pathways
underlying the observed increased activity in prefrontal areas. In
addition, further studies focusing on regional glucose metabolism
changes at the individual level in specific areas involved in the
mesocircuit would help to better understand the mechanisms of
recovery following zolpidem intake (Fridman et al., 2014).
Another theory, the “GABA impairment hypothesis” was
recently proposed by Pistoia et al. (2014) to explain the effect
of zolpidem on recovery of consciousness. This theory suggests
that zolpidem (as well as baclofen, a GABA-B agonist) may act
on consciousness recovery thanks to the restoration of a nor-
mal ratio between synaptic excitation and inhibition by reversing
the impairment of GABA in this population of severely brain-
injured patients. This hypothesis has the advantage to explain
the potential mode of action of both zolpidem and baclofen on
patient’s recovery. In some patients with an impaired balance of
cortical subcortical-cortical connections, the use of GABA ago-
nists would decrease excessive information and thus reorganize
an equilibrate dialogue among different brain nuclei and allow
proper information processing. Nevertheless, the time course of
the observed effect of these two drugs is different. For zolpi-
dem, the short-term effect that disappear when the plasma drug
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FIGURE 2 | Impaired brain metabolism after placebo and zolpidem
intake and areas showing relative recovery after zolpidem. Brain areas
showing impaired metabolism (in blue) following placebo and zolpidem
administration and regions which were impaired following placebo but
showed relative recovery of activity after zolpidem intake (in red). For
display purposes results are shown thresholded at uncorrected p < 0.001.
From left to right, medial right and left view, frontal and posterior view of a
3D rendered brain MRI.
FIGURE 3 | Normalized cerebral metabolic rate for glucose (nCMRGlc)
values in prefrontal cortices after placebo. Values reported for the cluster
using peak coordinates x, y, z = −22,56,24 after placebo and zolpidem
intake in patients, as compared to healthy controls (boxplot showing
median, 25–75% quartiles and inner fences).
concentration falls suggest rapid neurotransmitter changes. On
the other hand, for baclofen, its slow-onset effects suggest a phe-
nomenon of gradual neuroplasticity. Unfortunately, we cannot
verify this hypothesis with the method used in our study (i.e.,
FDG-PET) this will therefore need to be addressed in future
studies.
Finally, if all these theories can explain part of the mechanisms
underlying the paradoxical responses induced by zolpidem, they
do not explain why only less than 10% of the patients react posi-
tively to those GABA agonist drugs. Large cohort studies may help
investigating this question.
We have to highlight that our study included only three
patients, and all had a hypoxia; therefore, our results are not gen-
eralizable to the general DOC population (Adams et al., 2000).
Note also that not all the patients with post-anoxic DOC may
improve after zolpidem. In addition, the three patients were
very likely to suffer from depression prior to injury (as they all
attempted suicide), which may be a confounding factor. One
could argue that vigilance in MCS patients is fluctuating and the
behavioral improvement observed in the three patients could be
related to this bias. Nevertheless, these patients were in a chronic
stage (i.e., more stable in their responses) and they showed a dra-
matic recovery of functional communication/object use that has
not been observed before. These elements support the idea of a
diagnostic change induced by zolpidem intake.
Our results also underline a key role of the prefrontal cortices
in the recovery of functional communication and object use in
those hypoxic patients with chronic DOC. It is well known that
the prefrontal cortex has a major role in executive function and
working memory, a recovery of its functionality is therefore likely
to influence object use and recovery of communication. Our find-
ings partly corroborate previous case-studies (Nakayama et al.,
2006; Thibaut et al., 2012) reporting a decreased metabolism
in medial prefrontal and frontobasal regions, cingulate gyrus
and thalamus as a function of the consciousness impairments
in severely brain-injured patients. In addition, we observed a
relative decrease in brain metabolism in the left superior tem-
poral gyrus following zolpidem intake. This could be explained
by the reestablishment of top-down processes associated with the
reactivation of the prefrontal areas following zolpidem.
Taken together, the data suggest that the infrequent but exist-
ing paradoxical effect of zolpidem could be characteristic to
patients having suffered subcortical thalamic (as in all 3 cases here
reported) and/or striatal functional lesions preventing prefrontal
cortices to exhibit their normal function.
CONCLUSION
We observed an increased metabolism in prefrontal cortices fol-
lowing zolpidem intake, in line with the previously proposed
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mesocircuit model for recovery of consciousness in DOC (Schiff,
2010). Large cohort studies comparing brain structure, function
and mesocircuit connectivity of DOC zolpidem-responders as
compared to the vast majority of non-responders would allow to
better understand in which cases zolpidem might improve cog-
nitive function in such a clinically significant and yet transient
manner. Increasing our research efforts to understand the com-
mon denominator and neural mechanisms underlying these rare
cases responding to zolpidem could provide new avenues for pro-
moting therapeutic strategies improving the recovery of some
DOC patients with severe acquired brain damage.
AUTHOR CONTRIBUTIONS
Camille Chatelle designed the study, performed the statistical
analysis and drafted the manuscript with Aurore Thibaut. Olivia
Gosseries participated in medical data collection and helped
drafting the manuscript. Mohamed A. Bahri participated in the
design of the study and acquired behavioral and PET data. Athena
Demertzi collected behavioral and MRI data. Claire Bernard and
Roland Hustinx performed PET examination and preprocessed
the data. Luaba Tshibanda did the visual analysis of structural
MRI data. Marie-Aurélie Bruno revised the manuscript critically
for important methodological content. Steven Laureys partici-
pated in the design of the study and revised the manuscript
critically for important intellectual content. All authors read,
commented and approved the final manuscript.
ACKNOWLEDGMENTS
This study was supported by the National Funds for Scientific
Research (FNRS), Action de Recherche Concertée, Fonds
Léon Fredericq, James S. McDonnell Foundation, Mind
Science Foundation, University of Liège, the Belgian American
Educational Foundation (BAEF), the Fédération Wallonie
Bruxelles International (WBI) and the Belgian interuniversity
attraction pole. Camille Chatelle and Olivia Gosseries are funded
by the BAEF and WBI; Olivia Gosseries, Mohamed A. Bahri and
Athena Demertzi are FNRS post-doctoral researchers and Steven
Laureys is FNRS research director.
REFERENCES
Adams, J. H., Graham, D. I., and Jennett, B. (2000). The neuropathology of the
vegetative state after an acute brain insult. Brain 123(Pt 7), 1327–1338. doi:
10.1093/brain/123.7.1327
Brefel-Courbon, C., Payoux, P., Ory, F., Sommet, A., Slaoui, T., Raboyeau, G.,
et al. (2007). Clinical and imaging evidence of zolpidem effect in hypoxic
encephalopathy. Ann. Neurol. 62, 102–105. doi: 10.1002/ana.21110
Bruno, M. A., Majerus, S., Boly, M., Vanhaudenhuyse, A., Schnakers, C., Gosseries,
O., et al. (2012). Functional neuroanatomy underlying the clinical subcatego-
rization of minimally conscious state patients. J. Neurol. 259, 1087–1098. doi:
10.1007/s00415-011-6303-7
Bruno, M. A., Vanhaudenhuyse, A., Thibaut, A., Moonen, G., and Laureys, S.
(2011). From unresponsive wakefulness to minimally conscious PLUS and
functional locked-in syndromes: recent advances in our understanding of dis-
orders of consciousness. J. Neurol. 258, 1373–1384. doi: 10.1007/s00415-011-
6114-x
Calabresi, P., Centonze, D., and Bernardi, G. (2000). Cellular factors controlling
neuronal vulnerability in the brain: a lesson from the striatum. Neurology 55,
1249–1255. doi: 10.1212/WNL.55.9.1249
Clauss, R., and Nel, W. (2006). Drug induced arousal from the permanent vegeta-
tive state. NeuroRehabilitation 21, 23–28.
Clauss, R. P., Guldenpfennig, W. M., Nel, H. W., Sathekge, M. M., and
Venkannagari, R. R. (2000). Extraordinary arousal from semi-comatose state
on zolpidem. A case report. S. Afr. Med. J. 90, 68–72.
Cohen, L., Chaaban, B., and Habert, M. O. (2004). Transient improve-
ment of aphasia with zolpidem. N. Engl. J. Med. 350, 949–950. doi:
10.1056/NEJM200402263500922
Du, B, Shan, A, Zhang, Y, Zhong, X, Chen, D, and Cai, K. (2013). Zolpidem arouses
patients in vegetative state after brain injury: quantitative evaluation and
indications.Am. J. Med. Sci. 347, 178–182. doi: 10.1097/MAJ.0b013e318287c79c
Du, B., Shan, A., Zhang, Y., Zhong, X., Chen, D., and Cai, K. (2014).
Zolpidem arouses patients in vegetative state after brain injury: quan-
titative evaluation and indications. Am. J. Med. Sci. 347, 178–182. doi:
10.1097/MAJ.0b013e318287c79c
Feeney, D. M., and Baron, J. C. (1986). Diaschisis. Stroke 17, 817–830. doi:
10.1161/01.STR.17.5.817
Fridman, E. A., Beattie, B. J., Broft, A., Laureys, S., and Schiff, N. D. (2014). Regional
cerebral metabolic patterns demonstrate the role of anterior forebrain mesocir-
cuit dysfunction in the severely injured brain. Proc. Natl. Acad. Sci. U.S.A. 111,
6473–6478. doi: 10.1073/pnas.1320969111
Fridman, E. A., Calvar, J., Bonetto, M., Gamzu, E., Krimchansky, B. Z., Meli, F.,
et al. (2009). Fast awakening fromminimally conscious state with apomorphine.
Brain Inj. 23, 172–177. doi: 10.1080/02699050802649662
Giacino, J., Ashwal, S., Childs, N., Cranford, R., Jennett, B., Katz, D., et al. (2002).
The minimally conscious state: definition and diagnostic criteria. Neurology 58,
349–353. doi: 10.1212/WNL.58.3.349
Giacino, J., Kalmar, K., and Whyte, J. (2004). The JFK Coma Recovery Scale-
Revised: measurement characteristics and diagnostic utility. Arch. Phys. Med.
Rehabil. 85, 2020–2029. doi: 10.1016/j.apmr.2004.02.033
Giacino, J. T., Fins, J. J., Laureys, S., and Schiff, N. D. (2014). Disorders of con-
sciousness after acquired brain injury: the state of the science. Nat. Rev. Neurol.
10, 99–114. doi: 10.1038/nrneurol.2013.279
Giacino, J. T., Whyte, J., Bagiella, E., Kalmar, K., Childs, N., Khademi, A., et al.
(2012). Placebo-controlled trial of amantadine for severe traumatic brain injury.
N. Engl. J. Med. 366, 819–826. doi: 10.1056/NEJMoa1102609
Glassman, R. B. (1971). Recovery following sensorimotor cortical damage: evoked
potentials, brain stimulation and motor control. Exp. Neurol. 33, 16–29. doi:
10.1016/0014-4886(71)90098-7
Gosseries, O., Charland-Verville, V., Thonnard, M., Bodart, O., Laureys, S., and
Demertzi, A. (2013). Amantadine, apomorphine and zolpidem in the treat-
ment of disorders of consciousness. Curr. Pharm. Des. 20, 4167-4184. doi:
10.2174/13816128113196660654
Langtry, H. D., and Benfield, P. (1990). Zolpidem. A review of its pharmacodynamic
and pharmacokinetic properties and therapeutic potential. Drugs 40, 291–313.
doi: 10.2165/00003495-199040020-00008
Laureys, S., Celesia, G. G., Cohadon, F., Lavrijsen, J., Leon-Carrrion, J., Sannita,
W. G., et al. (2010). Unresponsive wakefulness syndrome: a new name for
the vegetative state or apallic syndrome. BMC Med. 8:68. doi: 10.1186/1741-
7015-8-68
Laureys, S., and Schiff, N. D. (2012). Coma and consciousness:
paradigms (re)framed by neuroimaging. Neuroimage 61, 478–491. doi:
10.1016/j.neuroimage.2011.12.041
Nakayama, N., Okumura, A., Shinoda, J., Nakashima, T., and Iwama, T. (2006).
Relationship between regional cerebral metabolism and consciousness distur-
bance in traumatic diffuse brain injury without large focal lesions: an FDG-
PET study with statistical parametric mapping analysis. J. Neurol. Neurosurg.
Psychiatry 77, 856–862. doi: 10.1136/jnnp.2005.080523
Phillips, C. L., Bruno, M. A., Maquet, P., Boly, M., Noirhomme, Q., Schnakers,
C., et al. (2011). “Relevance vector machine” consciousness classifier applied
to cerebral metabolism of vegetative and locked-in patients. Neuroimage 56,
797–808. doi: 10.1016/j.neuroimage.2010.05.083
Pistoia, F., Sara, M., Sacco, S., Franceschini, M., and Carolei, A. (2014). Silencing
the brain may be better than stimulating it. The GABA effect. Curr. Pharm. Des.
20, 4154–4166.
Sanger, D. J. (2004). The pharmacology and mechanisms of action of new gen-
eration, non-benzodiazepine hypnotic agents. CNS Drugs 18(Suppl. 1:9–15;
discussion 41), 3–5.
Sara, M., Sacco, S., Cipolla, F., Onorati, P., Scoppetta, C., Albertini, G., et al.
(2007). An unexpected recovery from permanent vegetative state. Brain Inj. 21,
101–103. doi: 10.1080/02699050601151761
Frontiers in Human Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 917 | 7
Chatelle et al. PET in zolpidem-responders MCS patients
Schiff, N. D. (2010). Recovery of consciousness after brain injury: a mesocircuit
hypothesis. Trends Neurosci. 33, 1–9. doi: 10.1016/j.tins.2009.11.002
Schiff, N. D., Giacino, J. T., Kalmar, K., Victor, J. D., Baker, K., Gerber, M.,
et al. (2007). Behavioural improvements with thalamic stimulation after severe
traumatic brain injury. Nature 448, 600–603. doi: 10.1038/nature06041
Schnakers, C., Hustinx, R., Vandewalle, G., Majerus, S., Moonen, G., Boly, M.,
et al. (2008a). Measuring the effect of amantadine in chronic anoxic min-
imally conscious state. J. Neurol. Neurosurg. Psychiatry 79, 225–227. doi:
10.1136/jnnp.2007.124099
Schnakers, C., Majerus, S., Giacino, J., Vanhaudenhuyse, A., Bruno, M., Boly, M.,
et al. (2008b). A French validation study of the Coma Recovery Scale-Revised
(CRS-R). Brain Inj. 22, 786–792. doi: 10.1080/02699050802403557
Seel, R. T., Sherer, M., Whyte, J., Katz, D. I., Giacino, J. T., Rosenbaum, A. M., et al.
(2010). Assessment scales for disorders of consciousness: evidence-based rec-
ommendations for clinical practice and research. Arch. Phys. Med. Rehabil. 91,
1795–1813. doi: 10.1016/j.apmr.2010.07.218
Shames, J. L., and Ring, H. (2008). Transient reversal of anoxic brain injury-related
minimally conscious state after zolpidem administration: a case report. Arch.
Phys. Med. Rehabil. 89, 386–388. doi: 10.1016/j.apmr.2007.08.137
Tecco, J. M., Wuilmart, P., Lasseaux, L., Wikler, D. Jr., Damhaut, P., Goldman,
S., et al. (1998). Cerebello-thalamo-cerebral diaschisis: a case report.
J. Neuroimaging 8, 115–116.
Thibaut, A., Bruno, M. A., Chatelle, C., Gosseries, O., Vanhaudenhuyse, A.,
Demertzi, A., et al. (2012). Metabolic activity in external and internal aware-
ness networks in severely brain-damaged patients. J. Rehabil. Med. 44, 487–494.
doi: 10.2340/16501977-0940
Thonnard, M., Gosseries, O., Demertzi, A., Lugo, Z., Vanhaudenhuyse, A., Marie-
Aurelie, B., et al. (2013). Effect of zolpidem in chronic disorders of con-
sciousness: a prospective open-label study. Funct. Neurol. 28, 259–264. doi:
10.11138/FNeur/2013.28.4.259
Whyte, J., and Myers, R. (2009). Incidence of clinically significant responses
to zolpidem among patients with disorders of consciousness: a prelimi-
nary placebo controlled trial. Am. J. Phys. Med. Rehabil. 88, 410–418. doi:
10.1097/PHM.0b013e3181a0e3a0
Whyte, J., Rajan, R., Rosenbaum, A., Katz, D., Kalmar, K., Seel, R., et al. (2014).
Zolpidem and restoration of consciousness. Am. J. Phys. Med. Rehabil. 93,
101–113. doi: 10.1097/PHM.0000000000000069
Williams, S. T., Conte, M. M., Goldfine, A. M., Noirhomme, Q., Gosseries, O.,
Thonnard,M., et al. (2013). Common resting brain dynamics indicate a possible
mechanism underlying zolpidem response in severe brain injury. Elife 2:e01157.
doi: 10.7554/eLife.01157
Witte, O. W., Bidmon, H. J., Schiene, K., Redecker, C., and Hagemann, G. (2000).
Functional differentiation of multiple perilesional zones after focal cerebral
ischemia. J. Cereb. Blood Flow Metab. 20, 1149–1165. doi: 10.1097/00004647-
200008000-00001
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 18 July 2014; accepted: 27 October 2014; published online: 02 December
2014.
Citation: Chatelle C, Thibaut A, Gosseries O, Bruno M-A, Demertzi A, Bernard C,
Hustinx R, Tshibanda L, Bahri MA and Laureys S (2014) Changes in cerebral
metabolism in patients with a minimally conscious state responding to zolpidem.
Front. Hum. Neurosci. 8:917. doi: 10.3389/fnhum.2014.00917
This article was submitted to the journal Frontiers in Human Neuroscience.
Copyright © 2014 Chatelle, Thibaut, Gosseries, Bruno, Demertzi, Bernard, Hustinx,
Tshibanda, Bahri and Laureys. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Human Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 917 | 8
